Universitätsklinikum Tübingen

10th International Tuebingen Symposium on Pediatric Solid Tumors & SIOPEL Autumn Meeting 2026

„Pediatric Liver Tumors: Translational Advances and Cutting-Edge Management“

November 26th – 28th, 2026 / Tuebingen, Germany

Tuebingen Symposium 2026

Scientific Program

Friday, November 27th, 2026
Oncology, biology/pathology, radiology and molecular imaging
08.00 – 08.20Arrival and registration
08.20 – 08.45Welcome and opening
08.45 – 10.15Oncology Session I
Pediatric HCC and HCN-NOS: Treatment, Unsolved Problems and Hot Topics
08.45 – 09.00
(10+5 min)
  • Pediatric HCC: what is different from adult HCC?
    Viola Weeda, Brussels
09.00 – 09.15
(10+5 min)
  • HCN-NOS: how should we treat it today?
    Kathelijne Kraal, Utrecht
09.15 – 09.30
(10+5 min)
  • Local control in pediatric HCC and HCN-NOS: resection, transplant or systemic therapy first?
    Sanjeev A. Vasudevan, Houston
09.30 – 09.45
(10+5 min)
  • Non-surgical local control in HCC: TACE, TARE and ablation – what can be translated to children?
    Timo Auer, Tuebingen
09.45 – 10.00
(10+5 min)
  • Immunotherapy and targeted therapy in pediatric HCC
    tba
10.00 – 10.15
(10+5 min)
  • Fibrolamellar carcinoma: biology-driven trials
    Juliane Walz, Tuebingen
10.20 – 10.40Coffee break
10.40 – 11.45Biology / Pathology Session
Classification, markers and translational diagnostics
10.40 – 10.53
(10+3 min)
  • Classification of pediatric hepatocellular tumors: what clinicians need to know
    Christian Vokuhl, Bonn
10.53 – 11.06
(10+3 min)
  • HCN-NOS: what can be defined today?
    Rita Alaggio, Rome
11.06 – 11.19
(10+3 min)
  • Molecular pathology of hepatoblastoma
    Torsten Pietsch, Bonn
11.19 – 11.32
(10+3 min)
  • Genetics and epigenetics in hepatoblastoma
    Roland Kappler, Munich
11.32 – 11.45
(10+3 min)
  • Biomarkers for future trials: ready now or still exploratory?
    Carolina Armengol, Badalona
11.50 – 12.40Lunch and poster viewing
12.40 – 14.35Oncology Session II
Hepatoblastoma trials and treatment after PHITT
12.40 – 13.00
(15+5 min)
  • European trials and strategy: From HB89 and SIOPEL-1 to PHITT: 35 years of hepatoblastoma therapy
    Irene Schmid, Munich
13.00 – 13.20
(15+5 min)
  • COG hepatoblastoma strategy: risk groups, toxicity and trial endpoints
    Allison O´Neil, Boston
13.20 – 13.40
(15+5 min)
  • JCCG/JPLT hepatoblastoma experience: chemotherapy response
    Eiso Hiyama, Hiroshima
13.40 – 13.53
(10+3 min)
  • Risk stratification in hepatoblastoma: What is out from CHIC?
    Arun Rangaswami, San Francisco
13.53 – 14.06
(10+3 min)
  • PHITT Roadmap: Progress, Priorities, and Plans
    Madhumita Dandapani, Nottingham
14.06 – 14.19
(10+3 min)
  • RELIVE data on relapsed liver tumors: what should be treated, studied and registered?
    tba
14.19 – 14.35
(16 min)
  • Expert Panel: What should PHITT 2 change in hepatoblastoma treatment?
    Session speakers
14.40 – 15.00Coffee break
15.00 – 16.12Radiology / Surgery Session
PRETEXT, resectability and imaging innovation
15.00 – 15.13
(10+3 min)
  • PRETEXT/POSTTEXT today: accuracy, reproducibility and revisions needed
    tba
15.13 – 15.26
(10+3 min)
  • Pulmonary metastases and lung nodules
    tba
15.26 – 15.39
(10+3 min)
  • Imaging vascular involvement and resectability
    Simon McGuirk, Birmingham
15.39 – 15.52
(10+3 min)
  • PRETEXT annotation factors: evolving definitions and their relevance for surgical decision-making
    Beate Häberle, Munich
15.52 – 16.12
(15+5 min)
  • Beyond anatomy: molecular imaging for biology-guided tumor treatment
    Johannes Schwenck, Tübingen
16.20 – 16.25Day 1 wrap-up
Optional after the scientific sessions: Tour of Castle Hohentübingen – "The place of the historically first discovery of DNA". Registration only.
19.00Conference dinner
Saturday, November 28th, 2026
Surgery, basic science and poster presentations
09.00 – 10.25Surgery Session I
Local control, transplant and advanced operative strategy
09.00 – 09.13
(10+3 min)
  • Non-transplant surgery for PRETEXT III/IV hepatoblastoma
    Steven Warmann, Berlin
09.13 – 09.26
(10+3 min)
  • Resection margins after chemotherapy: how much is enough?
    tba
09.26 – 09.39
(10+3 min)
  • Vascular reconstruction in advanced pediatric liver tumors
    Christoph Slavetinsky, Tuebingen
09.39 – 09.52
(10+3 min)
  • Liver transplantation: upfront, rescue or salvage?
    Gregory Tiao, Stanford
09.52 – 10.05
(10+3 min)
  • Robotic and minimally invasive liver surgery: what is realistic for children?
    Johann Pratschke, Berlin
10.05 – 10.25
(20 min)
  • Debate: extreme resection versus transplantation in pediatric liver tumors
    Pro resection: Jörg Fuchs / Piotr Czauderna
    Pro transplant: Silvio Nadalin / Sophie Branchereau
10.30 – 10.50Coffee break
10.50 – 12.12Basic Science and Novel Therapy Session
From biology to precision therapy
10.50 – 11.10
(15+5 min)
  • The liver tumor microenvironment in adults: from inflammation to immune escape
    Mathias Heikenwälder, Tuebingen
11.10 – 11.23
(10+3 min)
  • Genomic Landscape of Hepatoblastoma
    Genta Nagae, Tokyo
11.23 – 11.36
(10+3 min)
  • Plasticity of hepatoblastoma
    Theo Hirsch, Paris
11.36 – 11.49
(10+3 min)
  • Organoids and functional drug screening
    Weng Chuan Peng, Utrecht
11.49 – 12.02
(10+3 min)
  • New targets and immune therapies for liver tumors
    tba
12.02 – 12.12
(5+5 min)
  • tba
    Oral abstract slot
12.20 – 14.00Lunch
12.20 – 14.00Closed SIOPEL member session / SIOPEL business meeting
14.00 – 14.35Poster Presentations
(3+2 min per poster)
14.40 – 14.55Surgery Session II
Non-hepatoblastoma, non-HCC tumors
14.40 – 14.55
(10+5 min)
  • Surgery for benign and intermediate pediatric liver tumors: When and how to resect?
    Chiara Grimaldi, Rome
14.55 – 15.10
(10+5 min)
  • Surgery for non-hepatoblastoma malignant liver tumors
    Piotr Czauderna, Gdansk
15.10 – 15.25
(10+5 min)
  • Rhabdoid Tumors of the Liver: Treatment and Outcome
    Michael Frühwald, Augsburg
15.25 – 15.35
(5+5 min)
  • tba
    Oral abstract slot
15.40 – 15.55Closing ceremony
Online Registration